Sun Pharmaceutical Industries

75 billion, its biggest overseas acquisition to date. 99 billion, the company said in an exchange filing. The company said the acquisition is aligned with its strategy to scale up its innovative medicines business while strengthening its presence in established brands and branded generics. The deal will also enable Sun Pharma to enter the biosimilars segment as a top global player. 4 billion, while strengthening its position in women’s health and biosimilars. New Jersey-based Organon operates across women’s health, biosimilars, and established medicines, with a portfolio of over 70 products and a presence in more than 140 countries.

The transaction, approved by the boards of both companies, expected to close in early 2027, subject to regulatory approvals and Organon shareholders’ approval. Sun Pharma plans to fund the deal through a mix of internal accruals and debt financing. 9 billion. Commenting on the deal, Sun Pharma Executive Chairman Dilip Shanghvi said the acquisition would help build a stronger and more diversified platform, while Managing Director Kirti Ganorkar highlighted synergy and growth opportunities from the integration. 65 on the BSE in early trade on Monday.

–IANS 18/09/26 | 8:59 pm | Berkshire Hathaway 18/09/26 | 4:48 pm | Artificial intelligence India’s digital transformation is no longer limited to smartphones, digital payments or online government services. Behind the digital services used by millions of Indians every day is a powerful and expanding infrastructure of data centres, cloud ... 18/09/26 | 4:35 pm | BSE Benchmark equity indices Sensex and Nifty ended mixed on Friday as a drop in crude oil prices was overshadowed by weakness in IT stocks and Tata Group counters.